
Commentary|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLC
Author(s)Karen Reckamp, MD
Karen L. Reckamp, MD, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Learn more about the combination of cabozantinib and erlotinib for NSCLC > >
Articles in this issue
over 11 years ago
Update on Next-Generation Therapies for NSCLCover 11 years ago
Adverse Events Associated With CO-1686over 11 years ago
<em>RICTOR</em> Amplification in Lung Cancerover 11 years ago
Peer Discussion on Maintenance Therapy in NSCLCover 11 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under Way



































